Mass Tort brief
UK Mass Tort & Group Litigation Brief: Class Action Reforms and Global Liabilities
Ministers weigh stricter rules for opt-out lawsuits as UK giants face major liability trials in London and US courts.
Mass Tort
BHP's rejected appeal clears Stage 2 London trials — cementing UK parent company liability for overseas environmental disasters.
BackgroundThe 2015 Fundão dam collapse released 40 million cubic meters of toxic mining waste in Brazil, killing 19 people and destroying communities. English courts accepted jurisdiction over UK-domiciled parent entity BHP for liabilities arising from its overseas joint venture.
- The refusal of permission to appeal clears Stage 2 London High Court trials to evaluate individual causation and calculate specific compensation amounts.
- BHP faces financial claims from over 600,000 Brazilian individuals, 46 municipalities, and indigenous communities affected by the toxic waste spill.
- The decision cements English legal precedent holding UK parent corporations accountable in domestic courts for severe environmental damage caused by foreign subsidiaries.
Mass Tort
Ministers are reviewing opt-out class action rules — filtering funder-backed suits before rising legal risks undermine UK corporate competitiveness.
BackgroundThe UK introduced opt-out collective proceedings in 2015 to let representative claimants sue on behalf of whole consumer classes. Third-party litigation funding in Britain grew tenfold over the past decade to exceed £2.2 billion.
- Proposals under review include earlier judicial merits testing and mandatory disclosure of funding terms, potentially lowering the volume of speculative opt-out claims filed in London.
- Third-party litigation capital in Britain is projected to reach £3.7 billion by 2028, driving corporate lobbying for statutory guardrails against US-style mass litigation.
- The review seeks to preserve legitimate consumer redress while preventing excessive legal costs from depressing valuations of UK-listed companies.
Mass Tort
Reckitt faces its first federal baby formula trial — opening multi-billion-pound liability risks that could force an industry-wide settlement.
BackgroundMultidistrict litigation consolidates similar federal product liability cases before a single judge for pre-trial rulings. Bellwether trials test jury reactions to evidence, setting benchmarks that guide global settlement negotiations across thousands of claims.
- Plaintiffs allege Mead Johnson failed to warn doctors that formula significantly elevates the risk of necrotizing enterocolitis in premature babies, causing permanent organ damage or death.
- Industry analysts estimate total liability across US federal and state courts between £400 million and £8 billion, creating severe headwind for Reckitt stock.
- The federal trial follows state court proceedings that produced a $60 million verdict against Mead Johnson, accelerating pressure on management to negotiate a global settlement.
Mass Tort
AstraZeneca's US appellate victory closes contract litigation loopholes — confirming broad statutory immunity for emergency vaccine developers.
BackgroundThe US PREP Act grants emergency immunity to vaccine developers during declared public health emergencies. Plaintiffs attempted to bypass those tort protections by suing manufacturers for breach of clinical trial consent agreements.
- The Tenth Circuit Court of Appeals ruled that statutory PREP Act immunity applies broadly to contract-based injury reimbursement theories as well as torts.
- The precedential decision protects UK-headquartered pharmaceutical firms from contract-based litigation workarounds following emergency drug development programs.
- Appellate judges remanded the case to lower courts solely to verify whether clinical trial documents contained explicit, written language waiving statutory immunity.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
